C3 glomerulonephritis in a patient treated with anti–PD-1 antibody - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2020

C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

(1, 2) , (3) , (4, 5) , (1, 2)
1
2
3
4
5

Abstract

Immune checkpoint inhibitors (ICIs) have dramati-cally transformed the treatment of solid tumors. ICIsinduce an immune response against tumoral cells as aresult of the removal of T-cell inhibition [1]. The logicalcounterpart of turning off T-cell inhibitory mechanismsis the onset of immune-related adverse events (irAEs)that affect different organs. Although the most frequentrenal irAE is acute interstitial nephritis [2], we report afirst case of C3 glomerulonephritis (GN) associated withthe use of an antieProgrammed Cell Death 1 (PD-1)humanised antibody.
Not file

Dates and versions

inserm-02449014 , version 1 (22-01-2020)

Identifiers

Cite

Simon Ville, Christine Kandel-Aznar, Veronique Fremeaux-Bacchi, Fadi Fakhouri. C3 glomerulonephritis in a patient treated with anti–PD-1 antibody. European Journal of Cancer, 2020, 125, pp.46-48. ⟨10.1016/j.ejca.2019.11.011⟩. ⟨inserm-02449014⟩
24 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More